Geneka Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-11-2024
- Paid Up Capital ₹ 1.00 M
as on 07-11-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.22 Cr
as on 07-11-2024
About Geneka Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.22 Cr.
Anil Sharma and Deepti Shrma serve as directors at the Company.
- CIN/LLPIN
U24110UR2021PTC012701
- Company No.
012701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Geneka Drugs?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Anil Sharma | Director | 27-Jul-2021 | Current |
Deepti Shrma | Director | Current |
Financial Performance of Geneka Drugs.
Geneka Drugs Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
What is the Ownership and Shareholding Structure of Geneka Drugs?
In 2023, Geneka Drugs had a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Silver Crown Foods Private LimitedActive 2 years 1 month
Anil Sharma and Deepti Shrma are mutual person
- Geneka Pharmaceuticals Private LimitedActive 3 years 5 months
Anil Sharma and Deepti Shrma are mutual person
- Jineka Healthcare Private LimitedActive 10 years 11 months
Anil Sharma and Deepti Shrma are mutual person
- Devbhumi Pharmaceutical Analytical Testing And Training FoundationActive 2 years 3 months
Anil Sharma is a mutual person
- Smau International Industry & Trade ChambersInactive For E-Filing 8 months 2 days
Anil Sharma is a mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Hdfc Bank Limited Creation Date: 02 May 2024 | ₹4.72 Cr | Open |
Others Creation Date: 22 Feb 2022 | ₹5.00 M | Open |
How Many Employees Work at Geneka Drugs?
Geneka Drugs has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geneka Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geneka Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.